Carbohydrate Microarray Profiling of Glycan-Binding Antibodies and Lectins

聚糖结合抗体和凝集素的碳水化合物微阵列分析

• 批准号: 9779696
• 负责人: Jeffrey Gildersleeve
• 金额: $ 74.34万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9779696
• 关键词: Agonist; Antibodies; Antigens; Basic Science; Binding; Binding Proteins; Carbohydrates; Clinical; Communities; Diagnostic; Disease; Disease Progression; Evaluation; Goals; Lectin; Malignant Neoplasms; Microarray Analysis; Monitor; Monoclonal Antibodies; Play; Polysaccharides; Protein-Carbohydrate Interaction; Proteins; Reagent; Research; Role; Specificity; Therapeutic Agents; cancer cell; carbohydrate binding protein; design; high throughput technology; interest; tool; tumor progression

Cancer cells undergo dramatic changes in carbohydrate expression during the onset and progression of disease. As a result, there has been considerable interest in understanding why these changes occur, how they contribute to the disease, and exploiting these changes for clinical use. Carbohydrate binding antibodies and lectins play a critical role in this research for several reasons. First, antibodies and lectins are used extensively to detect and monitor changes in carbohydrate expression. In this capacity, they are used for basic research, as diagnostics, and as therapeutic agents. A comprehensive understanding of their specificity is critical for proper use and interpretation of results. Until recently, this information was not readily available. With the advent of carbohydrate microarray technology, or glycan arrays, we can now rapidly analyze binding of these proteins to a wide variety of carbohydrate antigens. In the past, we have screened a large set of commercially available lectin and antibody reagents used in the research community. We found that many of these reagents did not display the expected specificity. The information we provided regarding specificity will enable better use of these reagents and facilitate interpretation of results. In addition, the array can be used to develop new antibodies and lectins for monitoring new carbohydrate antigens. The array is being used to develop new monoclonal antibodies.

癌细胞在发作和疾病进展过程中碳水化合物表达的急剧变化。结果，人们对理解为什么发生这些变化，如何对疾病做出贡献并利用这些变化供临床使用引起了人们的兴趣。碳水化合物结合抗体和凝集素在这项研究中起着至关重要的作用，原因有几个。首先，抗体和凝集素被广泛用于检测和监测碳水化合物表达的变化。以这种能力，它们用于基础研究，作为诊断和治疗剂。对其特异性的全面了解对于正确使用和解释结果至关重要。直到最近，此信息还不容易获得。随着碳水化合物微阵列技术或聚糖阵列的出现，我们现在可以快速分析这些蛋白质与各种碳水化合物抗原的结合。过去，我们筛选了研究社区中使用的大量市售凝集素和抗体试剂。我们发现，其中许多试剂没有显示出预期的特异性。我们提供的有关特异性的信息将使这些试剂更好地使用这些试剂并促进结果的解释。此外，该阵列可用于开发新的抗体和凝集素，以监测新的碳水化合物抗原。该阵列用于开发新的单克隆抗体。